HIMA technology adoption study
This article was originally published in The Gray Sheet
Executive Summary
Rand Health is selected by the Health Industry Manufacturers Association to conduct a study on the adoption of new medical technology in managed care settings. Expected to be complete by late fall, the study will identify how managed care organizations currently review and pay for technology, and how device firms prepare for this process. The study "may reveal voluntary 'best practices' for introducing emerging technologies into the managed care environment," HIMA says
You may also be interested in...
Rand Corp.
"Managed Care and the Evaluation and Adoption of Emerging Technology" study is scheduled for release March 21. The study is intended to provide tips on how medical device manufacturers prepare for device evaluation and coverage decisions by managed care organizations. Sponsors of the study include the California Goldstrike Partnership of the State of California's Trade and Commerce Agency, the Economic Development Administration of the U.S. Department of Commerce, and the Health Industry Manufacturers Association (1"The Gray Sheet" May 24, 1999, In Brief)
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.